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background: Matrix metalloproteinase (MMP) species are upregulated in the failing human heart and influenced ventricular remodeling. We 
assessed the hypothesis that disparity between MMP-9 and tissue inhibitors of MMP-1 (TIMP-1) reflects the clinical manifestation and are related to 
prognostic risk in patients with systolic heart failure.
Methods: Circulating levels of MMP-9, TIMP-1 and Brain natriuretic peptide (BNP) were measured in 173 heart failure patients with reduced left 
ventricular ejection fraction <50%. Major adverse cardiovascular event (MACE) was assessed during the follow-up period (average of 88±49 months).
results: Levels of MMP-9, TIMP-1 and MMP-9/TIMP-1 ratio increased with the severity of New York Heart Association functional class (P for 
trend=0.003, 0.011 and 0.005, respectively). Patients who experienced MACE had high values of MMP-9 (80.6±159.5 versus 33.7±50.1 ng/ml, 
P=0.004). During the follow-up period, 44 patients had MACE. Kaplan-Meier analysis demonstrated a higher probability of MACE in the high values 
(>23.2) of MMP-9 group (P<0.001). Multivariate cox proportional hazard model showed that high level of MMP-9 was an independent predictor for 
MACE (Hazard ratio 3.129, 95%CI 1.438-6.812). Moreover, in the setting of combination of MMP-9 and BNP, even in low BNP (<210 pg/mL) group, 
the odd ratio of high MMP-9 value was 4.098 (95%CI 1.697-9.872) for MACE compared with low MMP-9 value group. In low BNP group, Kaplan-
Meier analysis demonstrated a higher probability of MACE in the high values (>23.2) of MMP-9 group (P=0.001).
conclusions: MMP-9 levels positively correlate with the severity of New York Heart Association class and the high value of MMP-9 is associated 
with MACE in heart failure. MMP-9 levels allow further risk stratification, suggesting the overexpressed MMP-9 level contributes to the occurrence of 
MACE in patients with heart failure and systolic dysfunction. 
